Cardiovascular Disease Clinical Trial
Official title:
Postprandial Glycemia in Association With Vascular Disease in Childhood Obesity
Verified date | April 2013 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The main purpose of this study is to determine whether treatment with acarbose attenuates post-prandial glycemic excursions in non-diabetic/pre-diabetic obese children as determined by continuous glucose monitoring systems (CGMS). To this effect the current pilot study involves a 6 week intervention with acarbose given to all subjects with either impaired glucose tolerance or an area under the curve of >130 mg/dl during the screening oral glucose tolerance test. Three consecutive days of CGMS are then compared to before and during the intervention. The secondary objective addressed in this protocol is the collection of baseline measures of endothelial function in obese and lean children. Even though the duration of acarbose treatment may be too short to demonstrate a vascular effect, the pre and post intervention data would serve as preliminary data for anticipated future studies that assess the vascular effect of reduced post-prandial blood glucose levels.
Status | Terminated |
Enrollment | 23 |
Est. completion date | September 2008 |
Est. primary completion date | September 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 12 Years to 25 Years |
Eligibility |
Obese Subjects: Inclusion Criteria: - Obesity (BMI > 97%tile for age and sex matched normative data) - Good general health, taking no medication on a chronic basis - Age 12-19 yrs, in puberty (girls: breast: Tanner stage II to V, boys: testicular volume >6ml) - Girls who are sexually active must use adequate birth control methods(such as barrier method or oral contraception) and must have a negative pregnancy test - Normal liver function tests Exclusion Criteria: - Raynaud's syndrome - Pregnancy or breastfeeding mothers - Smokers - Anemia (Hct < 35) - Baseline creatinine > 1.0 mg - Abnormal liver transaminases > 1.5X the upper limit of normal - Presence of endocrinopathies (Cushing syndrome, hypothyroidism) - Presence or history of gastrointestinal disorders (Inflammatory bowl disease, irritable bowl disease, hernia, ileus) - Presence of significant chronic illness of any kind - Drug therapy (examples of commonly occurring drug therapy include any drugs to treat asthma, hypertension, dyslipidemia, insulin resistance, depression) - Psychiatric disorders - History of substance abuse (including anorexic agents) Control Subjects: Inclusion Criteria: - Lean (BMI < 85%tile for age and sex matched normative data) - Good general health, taking no medication on a chronic basis - Age 12-25 yrs, in puberty (girls: breast: Tanner stage II to V, boys: testicular volume >6ml) - Girls who are sexually active must use adequate birth control methods (such as barrier method or oral contraception) and must have a negative pregnancy test Exclusion Criteria: - Raynaud's syndrome - Pregnancy or breastfeeding mothers - Smokers - Presence of endocrinopathies (Cushing syndrome, hypothyroidism Presence of significant chronic illness of any kind - Drug therapy (examples of commonly occurring drug therapy include any drugs to treat asthma, dyslipidemia, hypertension, depression) - Psychiatric disorders - History of substance abuse - First degree relative with either T1DM or T2DM - Presence of acanthosis nigricans |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Yale School of Medicine | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Percentage of Glucose Values = 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor | At baseline (before treatment) | No | |
Primary | Mean Percentage of Glucose Values = 140 mg/dl Over 72 Hours of Glucose Readings Measured With a Continuous Glucose Monitor | After 6 Weeks (post treatment) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|